狼疮肾炎代谢组学揭示anifrolumab通过抑制I型干扰素调节独特代谢物
基于TULIP-LN二期试验,对128例血清和119例尿液样本进行非靶向代谢组学分析,发现anifrolumab显著调节血清吲哚硫酸盐和胞嘧啶及尿液尿嘧啶和胞嘧啶,基线尿尿嘧啶可预测第52周对强化方案的应答。
要点
- 血清吲哚硫酸盐和胞嘧啶受anifrolumab调节最显著,基线水平与肾损伤指标相关。
- 尿液尿嘧啶和胞嘧啶受anifrolumab调节最显著,水平与疾病活动血清学标志物相关。
- 基线尿尿嘧啶水平可预测第52周对anifrolumab强化方案的应答。
核心结论
- 研究建立了狼疮肾炎患者I型干扰素信号、嘧啶代谢与尿毒症毒素之间的联系,支持评估尿尿嘧啶作为anifrolumab应答的潜在生物标志物。
研究设计与样本
- TULIP-LN(NCT02547922)二期试验中,患者接受标准治疗联合静脉anifrolumab或安慰剂,对128例血清和119例尿液样本进行非靶向代谢组学分析。
主要发现
- 血清中吲哚硫酸盐和胞嘧啶是受anifrolumab调节最显著的代谢物,基线水平与肾损伤指标相关。
- 尿液中尿嘧啶和胞嘧啶是受anifrolumab调节最显著的代谢物,其水平与疾病活动血清学标志物相关。
- 体外模型中anifrolumab降低了由吲哚硫酸盐上调的血管功能障碍和炎症标志物。
- 基线尿尿嘧啶水平预测第52周对anifrolumab强化方案的应答。
关键数值与推荐
- 血清样本128例,尿液样本119例。
- 基线尿尿嘧啶水平预测第52周对anifrolumab强化方案的应答。
临床怎么用
- 尿尿嘧啶可作为评估anifrolumab强化方案应答的潜在生物标志物进行进一步评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) commonly develop lupus nephritis (LN), the most frequent severe organ manifestation of this systemic autoimmune disease. Using serum and urine samples from a phase 2 trial in LN, we investigated that how the LN metabolome is modulated in response to type I interferon receptor blockade with anifrolumab, an approved treatment for moderate to severe SLE. METHODS: Patients in TULIP-LN (NCT02547922) received standard therapy plus intravenous anifrolumab or placebo. Untargeted metabolomics analysis was performed on serum and urine samples from 128 and 119 patients, respectively. Metabolites impacted by anifrolumab and their associations with clinical, serological and kidney measures of LN disease activity were examined. An in vitro model was used to validate the impact of anifrolumab on metabolite-induced inflammation. RESULTS: In serum, indoxyl sulfate (IS) and cytosine were the metabolites most modulated by anifrolumab, while baseline levels correlated with measures of kidney damage. In urine, uracil and cytosine were the most modulated by anifrolumab and levels of these metabolites were associated with serological markers of disease activity. Anifrolumab reduced markers of vascular dysfunction and inflammation upregulated by IS in in vitro models. Baseline urine uracil levels predicted response to anifrolumab intensive regimen at Week 52. CONCLUSION: Our findings establish a connection between type I interferon signalling, pyrimidine metabolism and uremic toxins in patients with LN and support the evaluation of urine uracil as a potential biomarker of response to anifrolumab.
引用
- Gavin PG, Allman EL, Jayne D, et al. Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial. RMD Open. 2025. PMID: 41052889. doi:10.1136/rmdopen-2025-005932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。